Scientific Industries Inc

Good day and welcome to the Scientific Industries Report 4-Year 2023 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on a touch-tone phone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Joe Dorme, Managing Partner. Please go ahead.

Thank you, Betsy. Good morning, and thank you for joining us today to review the 2023 full-year financial results for scientific industries, ended December 31, 2023. With us today on the call are Helena Santos, Chief Executive Officer, Daniel Grunes, CEO of Scientific Bioprocessing, and John Moore, Chairman. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of Scientific Industries during this conference call constitute forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under risk factors and documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2023. Forward-looking statements speak only as of the date the statements were made, A company can give no assurance that such forward-looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Now I'd like to turn the call over to Helena Santos, CEO of Scientific Industries. Helena?

Thank you, Joe, and thank you, everyone, for joining us today. So we entered 2024 having successfully raised the financing to complete the development and the launch of our two major technology platforms. Those platforms are, first, the Torbell Zivit family of pill counters, and second, the SBI DOTS multi-parameter platform. The connection between these two platforms is our value proposition of digitally simplifying science and automating our customers' workflows. The greatest technology visionaries of our times all agree that artificial intelligence or AI is going to be the biggest productivity advancement of our lifetimes. Together with our growing shareholder base, we have raised and deployed over $30 million to make certain your company and our customers are major beneficiaries of this coming wave. In giving today's update on the specifics of our progress on these two platforms, I'll just give some hints of how our customers will benefit from AI. I'll start with the Torbell Vivid platform. We committed to building the most comprehensive, automated pill counting system, and we have a terrific sales and development partner in RxSystems and Healthmark in Canada. And they've helped us steer our product development. We introduced the VividLight S, which can count pills at three times the speed of the original VividLight. at a great price point, and we have been very happy with the market share gains this system has allowed us to gain from the large installed base of mechanical pill counters. So the big news this year will be the introduction of the $13,000 price point Vivid Workstation in early summer. That will fulfill our strategy to offer the most complete line of automated pill counters on the market, ranging from $3,000 to $13,000. We will have five working prototypes ready to show the market and begin taking orders during the busy May to October trade show season. Our major partner, RX Systems, makes most of their sales at trade shows and Q1 is seasonally our lowest sales period historically. The availability of the workstation will mean we will then be ready to start showing the system to the major chains and we expect to be the main market for more sophisticated systems, where we feel there is a big unmet need for our products at the price point that we're speaking about. We have the only cloud-based system and have designed the workstation to be the first AI-enabled pill counter which will be able to sort pills by color and, as importantly, by shape. This is going to be a fundamental change in the way pharmacists do their work and it addresses a big headache associated with new pharmaceutical products introductions and to the supply chain. We expect that the AI enabled version of our Vivid Pill Counter will be trained and ready for the market in early 2025. We have an important technical mode and we'll be alone in this market with this capability to deliver value to our growing network of users. And with that, I will turn it over to Daniel so he can give us an update on our bioprocessing business. Daniel?